JP2022527293A - 複数の呼吸器ウイルス抗原に特異的なt細胞及びその作製方法及び治療での使用方法 - Google Patents
複数の呼吸器ウイルス抗原に特異的なt細胞及びその作製方法及び治療での使用方法 Download PDFInfo
- Publication number
- JP2022527293A JP2022527293A JP2021557608A JP2021557608A JP2022527293A JP 2022527293 A JP2022527293 A JP 2022527293A JP 2021557608 A JP2021557608 A JP 2021557608A JP 2021557608 A JP2021557608 A JP 2021557608A JP 2022527293 A JP2022527293 A JP 2022527293A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- hmpv
- piv
- influenza
- rsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 158
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 102
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 36
- 239000000427 antigen Substances 0.000 title claims description 702
- 108091007433 antigens Proteins 0.000 title claims description 701
- 102000036639 antigens Human genes 0.000 title claims description 701
- 238000004519 manufacturing process Methods 0.000 title description 17
- 230000001225 therapeutic effect Effects 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000009385 viral infection Effects 0.000 claims abstract description 52
- 208000036142 Viral infection Diseases 0.000 claims abstract description 50
- 241000342334 Human metapneumovirus Species 0.000 claims description 216
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 190
- 239000000203 mixture Substances 0.000 claims description 178
- 206010022000 influenza Diseases 0.000 claims description 146
- 210000004027 cell Anatomy 0.000 claims description 91
- 241000712003 Human respirovirus 3 Species 0.000 claims description 68
- 230000003612 virological effect Effects 0.000 claims description 67
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 49
- 102100038632 Presequence protease, mitochondrial Human genes 0.000 claims description 38
- 101150039699 M2-1 gene Proteins 0.000 claims description 37
- 102100038436 Neuronal pentraxin-1 Human genes 0.000 claims description 36
- 101710111966 Non-structural protein NP-1 Proteins 0.000 claims description 36
- 101710102575 Pre-neck appendage protein Proteins 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 28
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 26
- 230000000735 allogeneic effect Effects 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 208000024891 symptom Diseases 0.000 claims description 21
- 238000001727 in vivo Methods 0.000 claims description 16
- 241000712461 unidentified influenza virus Species 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 14
- 206010061598 Immunodeficiency Diseases 0.000 claims description 13
- 241000233866 Fungi Species 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 108010002586 Interleukin-7 Proteins 0.000 claims description 11
- 210000004443 dendritic cell Anatomy 0.000 claims description 11
- 230000002934 lysing effect Effects 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 238000002054 transplantation Methods 0.000 claims description 11
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 239000002158 endotoxin Substances 0.000 claims description 9
- 230000001400 myeloablative effect Effects 0.000 claims description 9
- 241000204031 Mycoplasma Species 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 230000006786 activation induced cell death Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 230000007813 immunodeficiency Effects 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 2
- 238000010586 diagram Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 description 44
- 241000711573 Coronaviridae Species 0.000 description 30
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 241000701161 unidentified adenovirus Species 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 241000315672 SARS coronavirus Species 0.000 description 17
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 12
- 241000701027 Human herpesvirus 6 Species 0.000 description 11
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 10
- 229960000329 ribavirin Drugs 0.000 description 10
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 10
- 206010035664 Pneumonia Diseases 0.000 description 9
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 8
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 8
- 241001678559 COVID-19 virus Species 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 7
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 7
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 208000037797 influenza A Diseases 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 241000709661 Enterovirus Species 0.000 description 6
- 102000001398 Granzyme Human genes 0.000 description 6
- 108060005986 Granzyme Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- 238000011510 Elispot assay Methods 0.000 description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 241000829111 Human polyomavirus 1 Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 241000124740 Bocaparvovirus Species 0.000 description 4
- 206010006448 Bronchiolitis Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 4
- 241000701460 JC polyomavirus Species 0.000 description 4
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 4
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 4
- 241000702670 Rotavirus Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 241000710886 West Nile virus Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000004176 Alphacoronavirus Species 0.000 description 3
- 241000008904 Betacoronavirus Species 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 101150046249 Havcr2 gene Proteins 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 3
- 241001109669 Human coronavirus HKU1 Species 0.000 description 3
- 241000482741 Human coronavirus NL63 Species 0.000 description 3
- 241001428935 Human coronavirus OC43 Species 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940121357 antivirals Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 210000000716 merkel cell Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940021993 prophylactic vaccine Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- -1 (eg Substances 0.000 description 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 2
- 101150009389 BZLF1 gene Proteins 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 101150059079 EBNA1 gene Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 101800001768 Exoribonuclease Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
- 101800001255 Putative 2'-O-methyl transferase Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 101800000578 Uridylate-specific endoribonuclease Proteins 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101800001779 2'-O-methyltransferase Proteins 0.000 description 1
- 101800003073 2'-O-methyltransferase nsp16 Proteins 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 101800001631 3C-like serine proteinase Proteins 0.000 description 1
- 101000748061 Acholeplasma phage L2 Uncharacterized 16.1 kDa protein Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 101000947615 Clostridium perfringens Uncharacterized 38.4 kDa protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101000964391 Enterococcus faecalis UPF0145 protein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101800001704 Guanine-N7 methyltransferase Proteins 0.000 description 1
- 101000748063 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.1 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101800003471 Helicase Proteins 0.000 description 1
- 101800002870 Helicase nsp13 Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101800000120 Host translation inhibitor nsp1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101000790840 Klebsiella pneumoniae Uncharacterized 49.5 kDa protein in cps region Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101100524762 Mesoplasma florum (strain ATCC 33453 / NBRC 100688 / NCTC 11704 / L1) ribV gene Proteins 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101800000512 Non-structural protein 1 Proteins 0.000 description 1
- 101800000933 Non-structural protein 10 Proteins 0.000 description 1
- 101800000934 Non-structural protein 13 Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 101800000514 Non-structural protein 4 Proteins 0.000 description 1
- 101800000508 Non-structural protein 5 Proteins 0.000 description 1
- 101800000507 Non-structural protein 6 Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101800004803 Papain-like protease Proteins 0.000 description 1
- 101800002227 Papain-like protease nsp3 Proteins 0.000 description 1
- 101800001074 Papain-like proteinase Proteins 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 101800001862 Proofreading exoribonuclease Proteins 0.000 description 1
- 101800002929 Proofreading exoribonuclease nsp14 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101800004575 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 101800001927 Uridylate-specific endoribonuclease nsp15 Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000006867 granzyme B production Effects 0.000 description 1
- 208000022182 gross hematuria Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 108700013356 oplunofusp Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本明細書で使用される場合、特許請求の範囲及び/又は明細書中で「含む(comprising)」という用語と組み合わせて使用される場合の「a」又は「an」という単語の使用は、「1つ」を意味し得るが、「1つ以上」、「少なくとも1つ」及び「1つ又は複数」の意味とも一致する。本発明の一部の実施形態は、本発明の1つ以上の要素、方法段階及び/又は方法からなり得るか又は本質的にそれらからなり得る。本明細書中に記載のあらゆる方法又は組成物が本明細書中に記載のあらゆる他の方法又は組成物に関して実行され得ることが企図される。
概要
ペプミックスライブラリの作製
VSTの作製
方法
別段の指示がない限り、以下に提供される実施例は、以下の材料及び方法を利用した。
フローサイトメトリー
免疫表現型検査
細胞内サイトカイン染色(ICS)
FoxP3染色
機能研究
酵素結合免疫スポット(ELIspot)
マルチプレックス
クロム放出アッセイ
実施例2
健常ドナーからのポリクローナルマルチR-VSTの作製
背景
ドナー及び細胞株
複数の呼吸器ウイルスに特異的なT細胞の作製及び表現型の特徴評価
結果
実施例3
マルチR-VSTの抗ウイルス特異性の特徴評価
実施例4
マルチR-VSTのインビトロ有効性の評価
実施例5
マルチR-VSTのインビボ有効性の評価
結論
実施例6
健康なドナーからのポリクローナルRSV特異的VSTの作製
結果
参考文献
1.Hodinka RL. Respiratory RNA Viruses. Microbiol Spectr. 2016;4(4).
2.Gill PJ, Richardson SE, Ostrow O, et al. Testing for Respiratory Viruses in Children: To Swab or Not to Swab. JAMA Pediatr. 2017;171(8):798-804.
3.Nair H, Simoes EA, Rudan I, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young childrenin 2010: a systematic analysis. Lancet. 2013;381(9875):1380-1390.
4.Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958.
5.Paulsen GC, Danziger-Isakov L. Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017;38(4):707-726.
6.Abbas S, Raybould JE, Sastry S, et al. Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles. Int J Infect Dis. 2017;62:86-93.
7.Hutspardol S, Essa M, Richardson S, et al. Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015;21(10):1802- 1807.
8.Lin R, Liu Q. Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2013;6:94.
9.Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220-1226.
10.Shah DP, Shah PK, Azzi JM, et al. Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.Cancer Lett. 2016;379(1):100-106.
11.Shah DP, Shah PK, Azzi JM, et al. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett. 2016;370(2):358-364.
12.Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59 Suppl 5:S344-351.
13.Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18(2):210-215.
14.Chemaly RF, Aitken SL, Wolfe CR, et al. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634-636.
15.Griffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev. 2017;30(1):277-319.
16.Walsh EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clin Chest Med. 2017;38(1):29-36.
17.Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.
18.Tzannou I, Papadopoulou A, Naik S, et al. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol.2017;35(31):3547-3557.
19.Aguayo-Hiraldo PI, Arasaratnam RJ, Tzannou I, et al. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017;216(2):153-161.
20.Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622-1632.
21.Tzannou I, Nicholas SK, Lulla P, et al. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017;216(6):678-687.
22.Goka E, Vallely P, Mutton K, et al. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. InfluenzaOther Respir Viruses. 2013;7(6):1079-1087.
23.Goka EA, Vallely PJ, Mutton KJ, et al. Single, dual and multiplerespiratory virus infections and risk of hospitalization and mortality. Epidemiol Infect. 2015;143(1):37-47.
24.Kouni S, Karakitsos P, Chranioti A, et al. Evaluation of viral co-infections in hospitalized and non-hospitalized children with respiratory infections using microarrays. Clin Microbiol Infect. 2013;19(8):772-777.
25.Lim FJ, de Klerk N, Blyth CC, et al. Systematic review and meta-analysis of respiratory viral coinfections in children. Respirology. 2016;21(4):648-655.
26.Stefanska I, Romanowska M, Donevski S, et al. Co-infections with influenza and other respiratory viruses. Adv Exp Med Biol. 2013;756:291-301.
27.Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016;22(5):965-970.
28.Zenilman JM, Fuchs EJ, Hendrix CW, et al. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res. 2015;123:114-119.
29.Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195-1204.
30.Vakil E, Sheshadri A, Faiz SA, et al. Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis. 2018;20(6):e12994.
31.Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly- generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21(11):2113-2121.
32.Heslop HE, Slobod KS, Pule MA, et al. Long-term outcomeof EBV-specific T-cellinfusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
33.Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood.2009;114(19):4283-4292.
34.Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644-2656.
35.Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015;125(12):1986-1994.
36.Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360-4367.
37.Peggs KS, Verfuerth S, Pizzey A, et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009;49(12):1851-1860.
38.Chen L, Zanker D, Xiao K, et al. Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein. J Virol. 2014;88(20):11760- 11773.
39.Grant EJ, Quinones-Parra SM, Clemens EB, et al. Human influenza viruses and CD8(+) T cell responses. Curr Opin Virol. 2016;16:132-142.
Claims (60)
- 複数のウイルス抗原を認識する細胞傷害性Tリンパ球(CTL)のポリクローナル集団を含む組成物であって、前記複数のウイルス抗原が、PIV由来の少なくとも1つの第1の抗原と、1つ以上の第2のウイルス由来の少なくとも1つの第2の抗原と、を含む、組成物。
- 前記CTLが、末梢血単核細胞(PBMC)を複数のペプミックスライブラリと接触させることによって作製され、各ペプミックスライブラリが、ウイルス抗原の少なくとも一部にまたがる複数の重複ペプチドを含み、前記複数のペプミックスライブラリのうち少なくとも1つが、PIV-3由来の第1の抗原にまたがり、前記複数のペプミックスライブラリのうち少なくとも1つのさらなるペプミックスライブラリが、各第2の抗原にまたがる、請求項1に記載の組成物。
- 前記CTLが、T細胞を複数のペプミックスライブラリで刺激した樹状細胞(DC)と接触させることによって作製され、各ペプミックスライブラリが、ウイルス抗原の少なくとも一部にまたがる複数の重複ペプチドを含み、前記複数のペプミックスライブラリのうち少なくとも1つが、PIV-3由来の第1の抗原にまたがり、前記複数のペプミックスライブラリのうち少なくとも1つのさらなるペプミックスライブラリが、各第2の抗原にまたがる、請求項1に記載の組成物。
- 前記CTLが、前記PIV-3抗原をコードする少なくとも1つのDNAプラスミド及び各第2の抗原をコードする少なくとも1つのDNAプラスミドでヌクレオフェクトされた樹状細胞(DC)とT細胞を接触させることによって作製される、請求項1に記載の組成物。
- 前記プラスミドが、少なくとも1つのPIV-3抗原及び前記第2の抗原のうち少なくとも1つをコードする、請求項4に記載の組成物。
- CD4+Tリンパ球及びCD8+Tリンパ球を含む、請求項1から5の何れか一項に記載の組成物。
- αβT細胞受容体を発現するCTLを含む、請求項1から6の何れか一項に記載の組成物。
- MHC拘束性CTLを含む、請求項1から7の何れか一項に記載の組成物。
- 前記1つ以上の第2のウイルスが、呼吸器合胞体ウイルス(RSV)、インフルエンザ、ヒトメタニューモウイルス(hMPV)及びそれらの組み合わせからなる群から選択される、請求項1から8の何れか一項に記載の組成物。
- 前記1つ以上の第2のウイルスが、呼吸器合胞体ウイルス(RSV)、インフルエンザ、ヒトメタニューモウイルス又はそれらの組み合わせを含む、請求項1から9の何れか一項に記載の組成物。
- 前記1つ以上の第2のウイルスが、呼吸器合胞体ウイルス(RSV)、インフルエンザ、ヒトメタニューモウイルス又はそれらの組み合わせからなる、請求項1から9の何れか一項に記載の組成物。
- 1、2、3又は4つの第1の抗原を含む、請求項1から11の何れか一項に記載の組成物。
- 前記第1の抗原が、PIV-3抗原M、PIV-3抗原HN、PIV-3抗原N、PIV-3抗原F及びそれらの組み合わせからなる群から選択される、請求項12に記載の組成物。
- 以下の4つの第1の抗原:PIV-3抗原M、PIV-3抗原HN、PIV-3抗原N、及びPIV-3抗原Fを含む、請求項12に記載の組成物。
- 2つ又は3つの第2のウイルスを含む、請求項1から14の何れか一項に記載の組成物。
- 3つの第2のウイルスを含む、請求項1から15の何れか一項に記載の組成物。
- 前記3つの第2のウイルスがインフルエンザ、RSV及びhMPVである、請求項16に記載の組成物。
- 各第2のウイルスあたり少なくとも2つの第2の抗原を含む、請求項1から17の何れか一項に記載の組成物。
- 1、2、3、4、5、6、7又は8個の第2の抗原を含む、請求項1から17の何れか一項に記載の組成物。
- 前記第2の抗原が、インフルエンザ抗原NP1、インフルエンザ抗原MP1、RSV抗原N、RSV抗原F、hMPV抗原M、hMPV抗原M2-1、hMPV抗原F、hMPV抗原N及びそれらの組み合わせからなる群から選択される、請求項1から19の何れか一項に記載の組成物。
- 前記第2の抗原が、インフルエンザ抗原NP1、インフルエンザ抗原MP1又はその両方を含む、請求項19に記載の組成物。
- 前記第2の抗原が、RSV抗原N、RSV抗原F又はその両方を含む、請求項19に記載の組成物。
- 前記第2の抗原が、hMPV抗原M、hMPV抗原M2-1、hMPV抗原F、hMPV抗原N及びそれらの組み合わせを含む、請求項19に記載の組成物。
- 前記第2の抗原が、インフルエンザ抗原NP1、インフルエンザ抗原MP1、RSV抗原N、RSV抗原F、hMPV抗原M、hMPV抗原M2-1、hMPV抗原F及びhMPV抗原Nのそれぞれを含む、請求項19に記載の組成物。
- 前記複数の抗原が、PIV-3抗原M、PIV-3抗原HN、PIV-3抗原N、PIV-3抗原F、インフルエンザ抗原NP1、インフルエンザ抗原MP1、RSV抗原N、RSV抗原F、hMPV抗原M、hMPV抗原M2-1、hMPV抗原F及びhMPV抗原Nを含む、請求項1から8の何れか一項に記載の組成物。
- 前記複数の抗原が、PIV-3抗原M、PIV-3抗原HN、PIV-3抗原N、PIV-3抗原F、インフルエンザ抗原NP1、インフルエンザ抗原MP1、RSV抗原N、RSV抗原F、hMPV抗原M、hMPV抗原M2-1、hMPV抗原F及びhMPV抗原Nからなるか又は基本的にそれらからなる、請求項1から8の何れか一項に記載の組成物。
- 前記CTLが、IL-7及びIL-4の両方の存在下でエクスビボで培養される、請求項1から26の何れか一項に記載の組成物。
- マルチウイルスCTLが、患者への投与のための準備が整うように、培養の9~18日以内に十分に増殖している、請求項1から27の何れか一項に記載の組成物。
- 前記CTLが、
a.無視できるアロ反応性;
b.患者から回収された抗原特異的T細胞の活性化誘導細胞死が、同じ患者から回収されたがIL-7及びIL-4の両方の存在下で培養されなかった対応する抗原特異的T細胞よりも少ないこと;及び
c.70%を超える生存率
から選択される1つ以上の特性を示す、請求項1から28の何れか一項に記載の組成物。 - 前記組成物が、培養下で少なくとも7日間、細菌及び真菌に対して陰性であり;5EU/ml未満のエンドトキシンを示し、マイコプラズマについて陰性である、請求項1から29の何れか一項に記載の組成物。
- 前記ペプミックスが化学合成されたものであり、任意選択的に>90%である純度である、請求項1から30の何れか一項に記載の組成物。
- 前記CTLがTh1極性化される、請求項1から31の何れか一項に記載の組成物。
- 前記CTLがウイルス抗原発現標的細胞を溶解可能である、請求項1から32の何れか一項に記載の組成物。
- 前記CTLが非感染自己又は同種異系標的細胞を顕著に溶解させない、請求項1から33の何れか一項に記載の組成物。
- 前記組成物が、培養下で少なくとも7日間細菌及び真菌に対して陰性であり;5EU/ml未満のエンドトキシンを示し、マイコプラズマについて陰性である、静脈内送達用に処方される請求項1から34の何れか一項に記載の組成物を含む医薬組成物。
- 前記標的細胞を請求項1から34の何れか一項に記載の組成物又は請求項35に記載の医薬組成物と接触させることを含む、標的細胞を溶解させる方法。
- 前記接触させることが、対象においてインビボで行われる、請求項36に記載の方法。
- 前記接触させることが、対象への前記CTLの投与を介してインビボで行われる、請求項36又は37に記載の方法。
- ウイルス感染の処置又は予防を必要とする対象に請求項1から34の何れか一項に記載の組成物又は請求項35に記載の医薬組成物を投与することを含む、ウイルス感染を処置又は予防する方法。
- 5x106~5x107CTL/m2が前記対象に投与される、請求項38又は39に記載の方法。
- 前記対象が免疫無防備状態である、請求項38から40の何れか一項に記載の方法。
- 前記対象が、急性骨髄性白血病、急性リンパ芽球性白血病又は慢性肉芽腫性疾患を有する、請求項38から41の何れか一項に記載の方法。
- 前記対象が、前記CTLを受ける前に、
a.強度軽減前処置を伴う適合血縁ドナー移植;
b.骨髄破壊的前処置を伴う適合非血縁ドナー移植;
c.強度軽減前処置を伴うハプロ一致移植;又は
d.骨髄破壊的前処置を伴う適合血縁ドナー移植
を受けた、請求項38から42の何れか一項に記載の方法。 - 前記対象が、
a.固形臓器移植を受けたことがある;
b.化学療法を受けたことがある;
c.HIV感染症を有する;
d.遺伝的免疫不全を有する;及び/又は
e.同種異系幹細胞移植を受けたことがある、
請求項38から40の何れか一項に記載の方法。 - 前記組成物が前記対象に複数回投与される、請求項38から44の何れか一項に記載の方法。
- 前記組成物の投与が、前記対象におけるウイルス感染症を効果的に処置又は予防し、前記ウイルス感染が、パラインフルエンザウイルス3型、呼吸器合胞体ウイルス、インフルエンザ及びヒトメタニューモウイルスからなる群から選択される、請求項38から45の何れか一項に記載の方法。
- 前記対象がヒトである、請求項38から46の何れか一項に記載の方法。
- 複数のウイルス抗原を認識する細胞傷害性Tリンパ球(CTL)のポリクローナル集団を含む組成物であって、前記複数のウイルス抗原が、パラインフルエンザウイルス3型(PIV-3)、呼吸器合胞体ウイルス、インフルエンザ及びヒトメタニューモウイルスから選択される少なくとも1つの抗原を含む、組成物。
- 複数のウイルス抗原を認識する細胞傷害性Tリンパ球(CTL)のポリクローナル集団を含み、前記複数のウイルス抗原が、パラインフルエンザウイルス3型、呼吸器合胞体ウイルス、インフルエンザ及びヒトメタニューモウイルスのそれぞれからの少なくとも1つの抗原を含む、請求項48に記載の組成物。
- 複数のウイルス抗原を認識する細胞傷害性Tリンパ球(CTL)のポリクローナル集団を含み、前記複数のウイルス抗原が、パラインフルエンザウイルス3型、呼吸器合胞体ウイルス、インフルエンザ及びヒトメタニューモウイルスのそれぞれからの少なくとも2つの抗原を含む、請求項48に記載の組成物。
- 前記複数の抗原が、PIV-3抗原M、PIV-3抗原HN、PIV-3抗原N、PIV-3抗原F、インフルエンザ抗原NP1、インフルエンザ抗原MP1、RSV抗原N、RSV抗原F、hMPV抗原M、hMPV抗原M2-1、hMPV抗原F及びhMPV抗原Nを含むか、それらからなるか又は基本的にそれらからなる、請求項48から50の何れか一項に記載の組成物。
- 静脈内送達用に処方された、請求項48から51の何れか一項に記載の組成物を含む、医薬組成物。
- 培養下で少なくとも7日間、細菌及び真菌に対して陰性であり、5EU/ml未満のエンドトキシンを示し、マイコプラズマについて陰性である、請求項52に記載の医薬組成物。
- 標的細胞を溶解する方法であって、前記標的細胞を請求項48から51の何れか一項に記載の組成物又は請求項52に記載の医薬組成物と接触させることを含む、方法。
- 前記接触させることが、対象においてインビボで行われる、請求項54に記載の方法。
- 前記接触させることが、対象への前記CTLの投与を介してインビボで行われる、請求項36又は37に記載の方法。
- ウイルス感染の処置又は予防を必要とする対象に請求項48から51の何れか一項に記載の組成物又は請求項52に記載の医薬組成物を投与することを含む、ウイルス感染を処置又は予防する方法。
- 前記組成物が前記対象に複数回投与される、請求項38から44の何れか一項に記載の方法。
- 前記組成物の投与が、前記対象におけるウイルス感染症を効果的に処置又は予防し、前記ウイルス感染が、パラインフルエンザウイルス3型、呼吸器合胞体ウイルス、インフルエンザ及びヒトメタニューモウイルスからなる群から選択される、請求項54から58の何れか一項に記載の方法。
- 前記対象がヒトである、請求項54から59の何れか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962823446P | 2019-03-25 | 2019-03-25 | |
US62/823,446 | 2019-03-25 | ||
PCT/US2020/024726 WO2020198366A1 (en) | 2019-03-25 | 2020-03-25 | Multi-respiratory virus antigen-specific t cells and methods of making and using the same therapeutically |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022527293A true JP2022527293A (ja) | 2022-06-01 |
JPWO2020198366A5 JPWO2020198366A5 (ja) | 2023-04-04 |
Family
ID=72608452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021557608A Pending JP2022527293A (ja) | 2019-03-25 | 2020-03-25 | 複数の呼吸器ウイルス抗原に特異的なt細胞及びその作製方法及び治療での使用方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220169986A1 (ja) |
EP (1) | EP3946438A4 (ja) |
JP (1) | JP2022527293A (ja) |
KR (1) | KR20210143277A (ja) |
CN (1) | CN113811328A (ja) |
AU (1) | AU2020247987A1 (ja) |
BR (1) | BR112021019120A2 (ja) |
CA (1) | CA3134813A1 (ja) |
CO (1) | CO2021013970A2 (ja) |
IL (1) | IL286629B1 (ja) |
MX (1) | MX2021011622A (ja) |
SG (1) | SG11202110541QA (ja) |
WO (1) | WO2020198366A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
HRP20221303T1 (hr) | 2012-02-09 | 2022-12-23 | Baylor College Of Medicine | SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI |
IL298359A (en) | 2015-09-18 | 2023-01-01 | Baylor College Medicine | Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment |
EP3967752A1 (en) * | 2020-09-15 | 2022-03-16 | Ingo Schmidt-Wolf | Virus specific cytokine-induced killer cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012002365A (es) * | 2009-08-24 | 2012-07-17 | Baylor College Medicine | Generación de lineas de linfocitos t citotóxicos con especificidad contra antígenos tumorales multiples o virus múltiples. |
IL298359A (en) * | 2015-09-18 | 2023-01-01 | Baylor College Medicine | Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment |
-
2020
- 2020-03-25 MX MX2021011622A patent/MX2021011622A/es unknown
- 2020-03-25 EP EP20777790.5A patent/EP3946438A4/en active Pending
- 2020-03-25 WO PCT/US2020/024726 patent/WO2020198366A1/en active Application Filing
- 2020-03-25 JP JP2021557608A patent/JP2022527293A/ja active Pending
- 2020-03-25 IL IL286629A patent/IL286629B1/en unknown
- 2020-03-25 US US17/593,747 patent/US20220169986A1/en active Pending
- 2020-03-25 CA CA3134813A patent/CA3134813A1/en active Pending
- 2020-03-25 KR KR1020217034430A patent/KR20210143277A/ko unknown
- 2020-03-25 SG SG11202110541QA patent/SG11202110541QA/en unknown
- 2020-03-25 BR BR112021019120A patent/BR112021019120A2/pt unknown
- 2020-03-25 CN CN202080035159.0A patent/CN113811328A/zh active Pending
- 2020-03-25 AU AU2020247987A patent/AU2020247987A1/en active Pending
-
2021
- 2021-10-19 CO CONC2021/0013970A patent/CO2021013970A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021013970A2 (es) | 2022-01-17 |
EP3946438A1 (en) | 2022-02-09 |
EP3946438A4 (en) | 2023-05-03 |
IL286629A (en) | 2021-10-31 |
US20220169986A1 (en) | 2022-06-02 |
MX2021011622A (es) | 2022-01-04 |
AU2020247987A1 (en) | 2021-11-11 |
CN113811328A (zh) | 2021-12-17 |
KR20210143277A (ko) | 2021-11-26 |
SG11202110541QA (en) | 2021-10-28 |
IL286629B1 (en) | 2024-06-01 |
WO2020198366A1 (en) | 2020-10-01 |
BR112021019120A2 (pt) | 2021-11-30 |
CA3134813A1 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220251509A1 (en) | Platform for activation and expansion of virus-specific t-cells | |
JP2022527293A (ja) | 複数の呼吸器ウイルス抗原に特異的なt細胞及びその作製方法及び治療での使用方法 | |
EP3801584B1 (en) | Cell-based vehicles for potentiation of viral therapy | |
US20200172864A1 (en) | T Cell Expansion Method | |
US20230293580A1 (en) | Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections | |
JP6999941B2 (ja) | 病原体からの免疫原性抗原同定および臨床的有効性との相関 | |
Riddell et al. | Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients | |
Vasileiou et al. | Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections | |
EP3000876B1 (en) | Method for preparing nk cells | |
KR20220051348A (ko) | 항원-특이적 t 세포 뱅크 및 이를 제조하고 치료학적으로 사용하는 방법 | |
Ip et al. | Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation | |
US20220257654A1 (en) | Antigen-specific t cell banks and methods of making and using the same therapeutically | |
Harvey et al. | Dendritic cell-natural killer cell cross-talk modulates T cell activation in response to influenza A viral infection | |
US20220177839A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
US20230071405A1 (en) | Natural Killer Cells for Treatment of Coronavirus Infection | |
US20230302130A1 (en) | Poly-donor cd4+ t cells expressing il-10 and uses thereof | |
WO2020251046A1 (ja) | 医薬組成物 | |
CN112399858A (zh) | 医学用途 | |
US20220088181A1 (en) | Virus specific cytokine-induced killer cells | |
Taechangam | Defining Feline Adipose-Derived Mesenchymal Stem Cells-Induced Alterations on T-lymphocytes and Implications for the Treatment of Viral and Inflammatory Conditions | |
Ip | Paediatric immune reconstitution with adenovirus adoptive immunotherapy post haematopoietic stem cell transplant | |
WO2023224599A1 (en) | Multivirus-specific t cell compositions and their use in treating or preventing viral infection or disease in solid organ transplant recipients | |
JP2023541046A (ja) | 操作されたiNKT細胞を使用したCOVID-19との闘い | |
Bollard et al. | Adoptive T‐cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230327 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240902 |